Corsicana & Co. decreased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,315 shares of the biopharmaceutical company’s stock after selling 357 shares during the period. Corsicana & Co.’s holdings in Pfizer were worth $226,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Worth Asset Management LLC bought a new stake in Pfizer during the 1st quarter worth about $29,000. Rinkey Investments bought a new stake in Pfizer during the 4th quarter worth about $32,000. Stuart Chaussee & Associates Inc. raised its holdings in Pfizer by 108.3% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 325 shares during the last quarter. Advanced Research Investment Solutions LLC raised its holdings in Pfizer by 339.3% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 659 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 509 shares during the last quarter. Finally, Bivin & Associates Inc. bought a new stake in Pfizer during the 4th quarter worth about $37,000. Institutional investors and hedge funds own 67.90% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have weighed in on PFE shares. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a report on Tuesday, June 28th. Berenberg Bank set a $44.00 price target on Pfizer in a research note on Wednesday, September 14th. UBS Group set a $59.00 price target on Pfizer in a research note on Thursday, September 1st. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. Finally, Barclays set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.
Pfizer Trading Up 1.5 %
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The firm had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. During the same quarter in the prior year, the firm posted $1.07 EPS. The business’s revenue was up 46.8% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 6.54 EPS for the current fiscal year.
Pfizer Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.59%. Pfizer’s payout ratio is presently 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.